No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MRUS240621P55000
- 3.10
- +1.25+67.57%
15min DelayClose May 31 16:00 ET
3.10High2.20Low
2.30Open1.85Pre Close68 Volume1.62K Open Interest55.00Strike Price16.78KTurnover46.44%IV-2.66%PremiumJun 21, 2024Expiry Date1.76Intrinsic Value100Multiplier18DDays to Expiry1.34Extrinsic Value100Contract SizeAmericanOptions Type-0.5936Delta0.0699Gamma16.77Leverage Ratio-0.0543Theta-0.0152Rho-9.95Eff Leverage0.0467Vega
Intraday
- 5D
- 1D
News
Bispecific and Trispecific Antibodies Market to Observe Stupendous Growth by 2035, Predicts DelveInsight | Key Companies - Akeso, Summit Therapeutics, Zymeworks, BeiGene, Jazz Pharmaceuticals, Merus, Roche
DelveInsight's Bispecifics/Trispecifics Market Insights report includes a comprehensive understanding of current treatment practices, emerging...
Express News | Merus NV : Jefferies Raises Target Price to $77 From $57
Merus Presented Interim Data On MCLA-145 Monotherapy And In Combination With Pembrolizumab At ASCO 2024
Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced upd
Express News | Merus NV : Leerink Partners Raises Target Price to $88 From $65
Express News | Merus NV Shares up 2.8% Premarket After Announcing Pricing of Upsized Public Offering of Common Shares
Merus Prices $400.2 Million Public Share Offering
Merus (MRUS) said late Wednesday it priced a public offering of about 7.6 million common shares at $53 per share. The gross proceeds from the offering are expected to total about $400.2 million. The o
Comments
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
3
Merus' high P/S ratio is worrisome due to underwhelming revenue forecasts. The company's declining revenue growth and below-industry growth predictions may cause a drop in the P/S ratio, risking shareholders' investments.
1
Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF(XBI.US$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index(.SPX.US$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...
28
1
$Merus(MRUS.US$ 71.55% is institutions owned, don't sell for cheap, at least 30.
Read more